Cargando…
Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors
The benefits of statins, commonly prescribed for hypercholesterolemia, in treating Alzheimer’s disease (AD) have not yet been fully established. A recent randomized clinical trial did not show any therapeutic effects of two statins on cognitive function in AD. Interestingly, however, the results of...
Autores principales: | Shinohara, Mitsuru, Sato, Naoyuki, Shimamura, Munehisa, Kurinami, Hitomi, Hamasaki, Toshimitsu, Chatterjee, Amarnath, Rakugi, Hiromi, Morishita, Ryuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005936/ https://www.ncbi.nlm.nih.gov/pubmed/24795626 http://dx.doi.org/10.3389/fnagi.2014.00071 |
Ejemplares similares
-
A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke
por: Kurinami, Hitomi, et al.
Publicado: (2016) -
Therapeutic vaccine for chronic diseases after the COVID-19 Era
por: Nakagami, Hironori, et al.
Publicado: (2021) -
Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice
por: Koriyama, Hiroshi, et al.
Publicado: (2020) -
Prevention of bleomycin-induced pulmonary fibrosis by a RANKL peptide in mice
por: Ju, Nan, et al.
Publicado: (2022) -
Inhibition of Neointima Formation through DNA Vaccination for Apolipoprotein(a): A New Therapeutic Strategy for Lipoprotein(a)
por: Kyutoku, Mariko, et al.
Publicado: (2013)